| Document |
Document Title |
|
WO/2024/118651A3 |
Provided herein are D domain containing polypeptides that specifically bind targets of interest, as are nucleic acids encoding the D domain containing polypeptides, vectors containing the nucleic acids and host cells containing the nucle...
|
|
WO/2024/124019A3 |
The disclosure provides variant AAV capsid proteins and AAV capsids and virus vectors comprising the same. The virus vectors described herein may have increased transduction in a target cell of interest, such as a hematopoietic stem cell...
|
|
WO/2024/130070A3 |
Provided herein are compositions including muscle (cardiac and skeletal) cell-targeting peptides linked thereto or inserted in a targeting protein of a recombinant vector having at least one exogenous peptide comprising Xn – non-RGD-n-...
|
|
WO/2024/151051A1 |
The present application relates to an antigen-binding fragment that forms a multimer and use thereof, and provides an antigen-binding fragment, a recombinant fusion protein comprising a multimer-forming domain linked to the antigen-bindi...
|
|
WO/2024/151213A2 |
The present disclosure provides compositions comprising an anti-CD8 chimeric activating receptor (CAR) and an anti-CD8 protein expression blocker, and methods of using such compositions in cancer therapy. The present disclosure provides ...
|
|
WO/2024/110672A3 |
The present invention relates to modified plants, methods of preparing same, and methods of reducing methane emissions in animals, in particular in ruminant livestock. Provided are plants and plant cells comprising nucleic acid construct...
|
|
WO/2024/149165A1 |
A triple mRNA vaccine for feline rhinotracheitis, feline calicivirus diseases, and feline panleukopenia, and a preparation method therefor. The triple mRNA vaccine is prepared by mixing mRNA expressing a feline herpesvirus gB protein, mR...
|
|
WO/2024/151972A1 |
A peptide with a primary structure of ((X1GLG)(X2GLG))m(XnGLG)nXT. Each X1 and Xn are independently selected from H, K and R; XT is X2G (SEQ ID NO: 28) or X2 (SEQ ID NO: 29); each X2 is independently selected from F, Y and W; and m is an...
|
|
WO/2024/130067A3 |
Provided herein are compositions including muscle (cardiac and/or skeletal) cell-targeting peptides linked thereto or inserted in a targeting protein of a recombinant vector having at least one exogenous peptide comprising Xn – RGD-n-m...
|
|
WO/2024/150158A1 |
The present disclosure relates to IL-7 polypeptides, compositions comprising IL-7 polypeptides, methods of making the same, and methods of using the IL-7 polypeptides for treatment of diseases. In one aspect, the disclosure relates to th...
|
|
WO/2024/150175A1 |
The present disclosure relates to activatable proteins which comprise cleavable moieties attached thereto which display an altered activity upon cleavage of the cleavable moieties. The present disclosure also relates to activatable IL-2 ...
|
|
WO/2024/151580A1 |
Polypeptides having an amino acid sequence at least 50% identical, not including any insertions, to the amino acid sequence of one of SEQ ID NO: 1-18, 31-36, and 43-45 are provided and their use, where the polypeptides include a pluralit...
|
|
WO/2024/149109A1 |
The present invention provides a pertussis toxin (PT) detoxification method, a detoxified PT antigen prepared by the method, and a diphtheria, tetanus and acellular pertussis combined vaccine. Formaldehyde and glutaraldehyde are used as ...
|
|
WO/2024/149249A1 |
Use of a reagent and/or device for detecting a human ABCG1 phosphorylation site in the preparation of a reagent for assessing the risk of tumor occurrence, diagnosing tumors or assessing tumor prognosis, and a kit; and use of a reagent f...
|
|
WO/2024/151814A1 |
The present disclosure provides a polypeptide complex comprising a target-binding polypeptide that binds a molecule on a target cell or a molecule in an extracellular matrix (ECM), and a small latent complex comprising, in particular, a ...
|
|
WO/2024/151982A1 |
The present disclosure relates to recombinant adeno-associated virus (rAAV) delivery of an acid alpha-glucosidase (GAA) polynucleotide. The disclosure provides rAAV vectors and methods of using the rAAV vectors for GAA gene therapy for P...
|
|
WO/2024/150177A1 |
The disclosure provides methods of treating a solid tumor in a subject comprising administration of a cell comprising a nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antigen-bi...
|
|
WO/2024/151133A1 |
The present application relates to: a polypeptide having carnosine synthase activity; a polynucleotide encoding the polypeptide; a microorganism comprising any one or more from among the polypeptide, the polynucleotide and a vector compr...
|
|
WO/2024/059688A3 |
The present disclosure provides compositions, methods, kits and uses for regulating blood-Central Nervous System (blood-CNS) barrier permeability (e.g., increasing or decreasing blood-CNS barrier permeability) by regulating signaling bet...
|
|
WO/2024/148369A1 |
The present disclosure provides targeted IL-12 affinity variants, pharmaceutical compositions comprising the variants, therapeutic cells expressing the variants, and methods or uses of the same for the treatment or prevention of a diseas...
|
|
WO/2024/148183A2 |
The present disclosure is directed to recombinant T-cell Receptors (TCRs) that binds Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) protein comprising a G12V mutation presented on a human leucocyte antigen-A (HLA-A)*03:01, polynucleot...
|
|
WO/2024/148324A1 |
GUCY2C T cell antigen coupler (TAC) polypeptides having (i) an antigen-binding domain that binds GUCY2C (e.g., a nanobody), (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor si...
|
|
WO/2024/147780A2 |
The invention relates to a new chemogenetic tool manipulating intracellular pH levels and hydrogen sulfide levels in living cells and tissues with high spatio-temporal resolution.
|
|
WO/2024/146953A1 |
Polypeptide and nucleic acid agents for treating diseases and conditions associated with complement are disclosed. Also disclosed are expression vectors, compositions and cells comprising the agents, and methods using the agents, e.g. fo...
|
|
WO/2024/148181A2 |
The present disclosure is directed to recombinant T-cell Receptors (TCRs) that binds Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) protein comprising a G12C mutation presented on a human leucocyte antigen-A (HLA-A)*11:01, polynucleot...
|
|
WO/2024/146379A1 |
This disclosure provides engineered TGFβRII variants, protein constructs, and methods of use thereof.
|
|
WO/2024/148332A1 |
Provided herein is a gene therapy for PKP2 (Plakophilin-2), e.g., using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter or a cardiac troponin T (HTNNT2) promoter. The capsid may be an AAV9 or AA...
|
|
WO/2023/196841A9 |
This document provides methods and materials for treating SYNGAP1-associated neurodevelopmental disorders (NDDs; e.g., SYNGAP1-related intellectual disability (SRID)). For example, viral vectors (e.g., adeno-associated viral (AAV) vector...
|
|
WO/2024/148130A2 |
A non-naturally occurring test molecule for use in a cell-based screening method, wherein the molecule comprises: a molecule of interest comprising a message/address peptide; a linker sequence; and an anchor sequence which anchors the te...
|
|
WO/2024/146575A1 |
Provided in the present disclosure are a variant of interleukin-2 and the use thereof. Specifically provided in the present disclosure is a variant protein of interleukin-2 (IL-2) or a fragment thereof. Compared with the amino acid seque...
|
|
WO/2024/148178A2 |
The present disclosure is directed to recombinant T-cell Receptors (TCRs) that binds Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) protein comprising a G12C mutation presented on a human leucocyte antigen-A (HLA-A)*03:01, polynucleot...
|
|
WO/2024/146936A1 |
The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PIWIL1 peptide-HLA complex. The invention also relates to the use of such molecules for the treatment of mali...
|
|
WO/2024/147836A1 |
Provided herein are recombinant host cells, compositions, and methods for the production of the sesquiterpenoids: alpha-humulene, beta-caryophyllene, valencene, delta-cadinene, delta-guaiene, germacrene A, germacrene D, beta- cubebene, v...
|
|
WO/2024/146951A1 |
The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PRAME peptide-HLA complex. In particular, the present invention relates to binding molecules that bind to PYL...
|
|
WO/2024/146898A1 |
The invention pertains to a mutant NAL1 protein for increasing test weight, and a nucleic acid molecule, chimeric gene, vector and host cell comprising a sequence encoding said mutant NAL1 protein. The invention further pertains to a hos...
|
|
WO/2024/148337A1 |
The application provides novel viral envelope glycoproteins for pseudotyping viral vectors, novel designs for synthetic antigen receptors (SARs), novel signaling chains for construction of SARs, novel antigen binding domains, and novel m...
|
|
WO/2024/146628A1 |
The disclosure relates to an engineered immune cell expressing one or more mutant tyrosine kinases (e.g., LYNT319D, LYNT319M, SRCV326K) and methods of use thereof. The disclosure also relates to one or more mutant tyrosine kinases (e.g.,...
|
|
WO/2024/147503A1 |
The present invention relates to TROP2 immunogenic peptides and a use thereof. The TROP2 immunogenic peptide according to the present invention selectively binds to MHC class II to enhance only the immunogenicity of specific immune cells...
|
|
WO/2024/147897A2 |
Provided herein are TROP2 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such TROP2 binding proteins. Also d...
|
|
WO/2024/148275A1 |
The present disclosure is directed to leucine zipper-based sorting systems adapted to facilitate the expression and coordination of polypeptide sequences capable of improving the function of CAR T cells. The systems enable the generation...
|
|
WO/2024/148185A2 |
The present disclosure is directed to recombinant T-cell Receptors (TCRs) that binds Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) protein comprising a G12V mutation presented on a human leucocyte antigen-A (HLA-A)*11:01, polynucleot...
|
|
WO/2024/148315A1 |
Described herein are methods for treating, repairing or ameliorating diseases, disorders, or injuries related to dry eye disease, wound healing, and osteoarthritis with megakaryocyte derivatives. Also, described herein are methods for ge...
|
|
WO/2024/148095A1 |
A nitrogen fixation method includes combining water and a gas comprising N2 and O2 in a reactor to yield an aqueous mixture, generating an electrical discharge in the aqueous mixture, thereby creating a non-thermal plasma in the aqueous ...
|
|
WO/2024/148243A1 |
Provided are antibodies that bind to interleukin-18 binding protein (IL-18BP) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of cancers and other...
|
|
WO/2024/145858A1 |
Disclosed in the present invention are a DNA-TRAIL composite, a method for preparing same, a kit, a method for using same to treat tumors, and the use thereof in treatment of tumors. The DNA-TRAIL composite comprises a DNA origami struct...
|
|
WO/2024/148212A2 |
The present invention relates to compositions and methods for generating modified T cells comprising nucleic acids encoding a T cell receptor (TCR) specific for Sox2 protein. Also included are methods and pharmaceutical compositions comp...
|
|
WO/2024/147113A1 |
Provided herein are glycoengineered polypeptides comprising a first moiety comprising one or more peptides that specifically binds to an anti-podocyte autoantibody and a second moiety comprising one or more glycans conjugated to the firs...
|
|
WO/2024/147362A1 |
The present invention relates to: a composition for improving retinal function, the composition comprising at least one protein selected from the group consisting of chemerin, NPC2, and SMOC1; and a method for producing retinal ganglion ...
|
|
WO/2024/147809A1 |
Described herein are methods for diagnosing and treating mycosis fungoides (MF) and cutaneous T cell lymphoma (CTCL), e.g., for making a differential diagnosis of CTCL/MF versus other skin conditions.
|
|
WO/2023/195805A9 |
The present invention relates to a drug delivery system that specifically binds to integrin beta 2 (ITGB2) on M2 tumor-associated macrophages. The drug delivery system comprising an ITGB2-binding moiety allowing specific binding to ITGB2...
|
